Global Post-Traumatic Stress Disorder (PTSD) Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Post-Traumatic Stress Disorder (PTSD) treatment during 2019. Clinical development activities are being undertaken by more than 30 companies including Actinogen Medical Ltd , Addex Therapeutics Ltd, Amorsa Therapeutics Inc, Anagin Inc, Aptinyx Inc and others.
A Significant contribution to the Post-Traumatic Stress Disorder (PTSD) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Post-Traumatic Stress Disorder (PTSD) pipeline included 30 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Post-Traumatic Stress Disorder (PTSD) condition and increased access to investments is encouraging growth of Post-Traumatic Stress Disorder (PTSD) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Post-Traumatic Stress Disorder (PTSD) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Post-Traumatic Stress Disorder (PTSD) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Post-Traumatic Stress Disorder (PTSD) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Post-Traumatic Stress Disorder (PTSD). Further, orphan drug status, fast track designation, grants awarded and other special status for Post-Traumatic Stress Disorder (PTSD) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Post-Traumatic Stress Disorder (PTSD) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Post-Traumatic Stress Disorder (PTSD) Pipeline candidates-
A Significant contribution to the Post-Traumatic Stress Disorder (PTSD) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Post-Traumatic Stress Disorder (PTSD) pipeline included 30 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Post-Traumatic Stress Disorder (PTSD) condition and increased access to investments is encouraging growth of Post-Traumatic Stress Disorder (PTSD) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Post-Traumatic Stress Disorder (PTSD) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Post-Traumatic Stress Disorder (PTSD) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Post-Traumatic Stress Disorder (PTSD) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Post-Traumatic Stress Disorder (PTSD). Further, orphan drug status, fast track designation, grants awarded and other special status for Post-Traumatic Stress Disorder (PTSD) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Post-Traumatic Stress Disorder (PTSD) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Post-Traumatic Stress Disorder (PTSD) Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Post-Traumatic Stress Disorder (PTSD) drugs
- Late phase: Phase 3 and in-approval Post-Traumatic Stress Disorder (PTSD) drugs
- Company overview
- Snapshot
- Post-Traumatic Stress Disorder (PTSD) therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Post-Traumatic Stress Disorder (PTSD)- Disease Overview
2.2 Post-Traumatic Stress Disorder (PTSD)- Pipeline Snapshot
2.3 Post-Traumatic Stress Disorder (PTSD)- Pipeline Drugs by Phase
2.4 Post-Traumatic Stress Disorder (PTSD)- Pipeline Drugs by Company
2.5 Post-Traumatic Stress Disorder (PTSD)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Actinogen Medical Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.2 Addex Therapeutics Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.3 Amorsa Therapeutics Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.4 Anagin Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.5 Aptinyx Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.6 Armgo Pharma Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.7 Artelo Biosciences Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.8 Azevan Pharmaceuticals Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.9 Catalyst Pharmaceuticals Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.10 Chronos Therapeutics Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.11 Corcept Therapeutics Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.12 Eli Lilly and Co Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.13 Embera NeuroTherapeutics Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.14 EpiVario Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.15 HMNC Brain Health Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.16 HydRx Farms Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.17 Immodulon Therapeutics Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.18 Johnson & Johnson Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.19 Kdac Therapeutics Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.20 Lixte Biotechnology Holdings Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.21 NeuroNascent Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.22 NeuroRx Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.23 Neurovation Labs Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.24 Omeros Corporation Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.25 One World Cannabis Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.26 Otsuka Holdings Co Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.27 Quoin Pharmaceuticals Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.28 Seelos Therapeutics Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.29 SpringWorks Therapeutics LLC Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.30 Tonix Pharmaceuticals Holding Corp Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Post-Traumatic Stress Disorder (PTSD)- Phase 1 Drug Details
4.2 Post-Traumatic Stress Disorder (PTSD)- Phase 1 Drug Overview
4.3 Post-Traumatic Stress Disorder (PTSD)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Post-Traumatic Stress Disorder (PTSD)- Phase 2 Drug Details
5.2 Post-Traumatic Stress Disorder (PTSD)- Phase 2 Drug Overview
5.3 Post-Traumatic Stress Disorder (PTSD)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Post-Traumatic Stress Disorder (PTSD)- Phase 3 Drug Details
6.2 Post-Traumatic Stress Disorder (PTSD)- Phase 3 Drug Overview
6.3 Post-Traumatic Stress Disorder (PTSD)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Post-Traumatic Stress Disorder (PTSD)- Pre-clinical Phase Drug Details
7.2 Post-Traumatic Stress Disorder (PTSD)- Pre-clinical Phase Drug Overview
7.3 Post-Traumatic Stress Disorder (PTSD)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Post-Traumatic Stress Disorder (PTSD)- Disease Overview
2.2 Post-Traumatic Stress Disorder (PTSD)- Pipeline Snapshot
2.3 Post-Traumatic Stress Disorder (PTSD)- Pipeline Drugs by Phase
2.4 Post-Traumatic Stress Disorder (PTSD)- Pipeline Drugs by Company
2.5 Post-Traumatic Stress Disorder (PTSD)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Actinogen Medical Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.2 Addex Therapeutics Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.3 Amorsa Therapeutics Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.4 Anagin Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.5 Aptinyx Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.6 Armgo Pharma Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.7 Artelo Biosciences Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.8 Azevan Pharmaceuticals Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.9 Catalyst Pharmaceuticals Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.10 Chronos Therapeutics Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.11 Corcept Therapeutics Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.12 Eli Lilly and Co Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.13 Embera NeuroTherapeutics Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.14 EpiVario Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.15 HMNC Brain Health Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.16 HydRx Farms Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.17 Immodulon Therapeutics Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.18 Johnson & Johnson Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.19 Kdac Therapeutics Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.20 Lixte Biotechnology Holdings Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.21 NeuroNascent Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.22 NeuroRx Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.23 Neurovation Labs Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.24 Omeros Corporation Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.25 One World Cannabis Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.26 Otsuka Holdings Co Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.27 Quoin Pharmaceuticals Ltd Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.28 Seelos Therapeutics Inc Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.29 SpringWorks Therapeutics LLC Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
3.30 Tonix Pharmaceuticals Holding Corp Post-Traumatic Stress Disorder (PTSD) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Post-Traumatic Stress Disorder (PTSD)- Phase 1 Drug Details
4.2 Post-Traumatic Stress Disorder (PTSD)- Phase 1 Drug Overview
4.3 Post-Traumatic Stress Disorder (PTSD)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Post-Traumatic Stress Disorder (PTSD)- Phase 2 Drug Details
5.2 Post-Traumatic Stress Disorder (PTSD)- Phase 2 Drug Overview
5.3 Post-Traumatic Stress Disorder (PTSD)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Post-Traumatic Stress Disorder (PTSD)- Phase 3 Drug Details
6.2 Post-Traumatic Stress Disorder (PTSD)- Phase 3 Drug Overview
6.3 Post-Traumatic Stress Disorder (PTSD)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Post-Traumatic Stress Disorder (PTSD)- Pre-clinical Phase Drug Details
7.2 Post-Traumatic Stress Disorder (PTSD)- Pre-clinical Phase Drug Overview
7.3 Post-Traumatic Stress Disorder (PTSD)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
